Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
22,068 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00340405 | Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, China | completed | — | 9,759 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03182244 | A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation | completed | Phase 3 | 276 | Astellas Pharma IncINDUSTRY | 5 | Sep 22, 2026 |
| clinicaltrials |
| NCT04221204 | A Monotherapy in Subjects With Advanced Solid Tumors | completed | Phase 1 | 23 | 3D Medicines (Beijing) Co., Ltd.INDUSTRY | 2 | Sep 22, 2026 | clinicaltrials |
| NCT05009836 | Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC(SANOVO) | active not recruiting | Phase 3 | 412 | HutchmedINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05201066 | Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | active not recruiting | Phase 2 | 33 | Novartis PharmaceuticalsINDUSTRY | 15 | Sep 22, 2026 | clinicaltrials |
| NCT05376345 | BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 24 | Shanghai Changzheng HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05471843 | Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 125 | BeOne MedicinesINDUSTRY | 14 | Sep 22, 2026 | clinicaltrials |
| NCT05564806 | Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 | 9 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05745740 | A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | not yet recruiting | Phase 1 / Phase 2 | 26 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05939414 | An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.(PSMA-DC) | recruiting | Phase 3 | 450 | Novartis PharmaceuticalsINDUSTRY | 27 | Sep 22, 2026 | clinicaltrials |
| NCT06140836 | A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | active not recruiting | Phase 3 | 190 | Bristol-Myers SquibbINDUSTRY | 21 | Sep 22, 2026 | clinicaltrials |
| NCT06712316 | Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | recruiting | Phase 2 / Phase 3 | 1,580 | BioNTech SEINDUSTRY | 22 | Sep 22, 2026 | clinicaltrials |
| NCT06780670 | Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy(PSMAcTION) | recruiting | Phase 2 / Phase 3 | 443 | Novartis PharmaceuticalsINDUSTRY | 13 | Sep 22, 2026 | clinicaltrials |
| NCT06855277 | Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC(AcTFirst) | recruiting | Phase 3 | 940 | Novartis PharmaceuticalsINDUSTRY | 12 | Sep 22, 2026 | clinicaltrials |
| NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | recruiting | Phase 3 | 630 | Mirati Therapeutics Inc.INDUSTRY | 35 | Sep 22, 2026 | clinicaltrials |
| NCT07100080 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | recruiting | Phase 2 / Phase 3 | 500 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 22, 2026 | clinicaltrials |
| NCT07114601 | A Study of LY4257496 in Participants With Cancer (OMNIRAY)(OMNIRAY) | recruiting | Phase 1 | 421 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 22, 2026 | clinicaltrials |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | recruiting | Phase 3 | 800 | Eli Lilly and CompanyINDUSTRY | 19 | Sep 22, 2026 | clinicaltrials |
| NCT07213791 | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors(FiREBOLT) | recruiting | Phase 1 | 241 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 22, 2026 | clinicaltrials |
| NCT07213804 | A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer(FRAmework-01) | recruiting | Phase 3 | 1,630 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 22, 2026 | clinicaltrials |
| NCT07218341 | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 4 | 150 | Eli Lilly and CompanyINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT07218380 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract(FORAGER-2) | recruiting | Phase 3 | 450 | Eli Lilly and CompanyINDUSTRY | 19 | Sep 22, 2026 | clinicaltrials |
| NCT07228247 | A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 147 | HutchmedINDUSTRY | 2 | Sep 22, 2026 | clinicaltrials |
| NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer | recruiting | Phase 3 | 614 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT07415031 | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | recruiting | Phase 2 | 170 | Mirati Therapeutics Inc.INDUSTRY | 20 | Sep 22, 2026 | clinicaltrials |
| NCT07429318 | Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer(GC/GEJC) | active not recruiting | — | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07452055 | Large Language Model-Based Emotional Management for Breast Cancer Patients(EMBRACE) | active not recruiting | N/A | 440 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07522476 | A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 30 | Virogin Biotech Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07565740 | Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07583550 | Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 43 | Jiangmen Central HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07596134 | Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC(HLP1-1331) | not yet recruiting | N/A | 166 | Zhejiang UniversityOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07620951 | Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China | completed | Phase 1 | 6 | Alpha Biopharma (Jiangsu) Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07653685 | A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer. | recruiting | Phase 1 / Phase 2 | 71 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07682870 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 42 | Virogin Biotech Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07728019 | Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM | recruiting | Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07746635 | Fecal Microbiota Transplantation for Obese Women With Polyendocrine Metabolic Ovarian Syndrome(FMT-PMOS) | recruiting | N/A | 201 | Shanghai Changzheng HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07763652 | A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07772934 | VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 260 | VelaVigo Bio IncINDUSTRY | 2 | Sep 22, 2026 | clinicaltrials |
| NCT07829549 | Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations | not yet recruiting | Phase 3 | 540 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07832448 | Microsurgical Resection Combined With Photodynamic Therapy for Recurrent Glioblastoma(PDT-rGBM) | active not recruiting | N/A | 10 | Yonggao MouOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833046 | Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection | not yet recruiting | — | 40 | RenJi HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833085 | CAIX-targeted PET/CT in Solid Tumors(CAIX-PET) | not yet recruiting | N/A | 100 | Zhongnan HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833124 | Multiphase CT Deep Learning for Bosniak II-III Renal Cysts | completed | — | 223 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833241 | Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC(ZSPAC-22) | not yet recruiting | Phase 2 | 56 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833319 | Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer(PKUCH-R10) | recruiting | Phase 2 | 26 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833657 | Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases(ITST-ADC-LM) | not yet recruiting | Phase 2 | 28 | Jiuda ZhaoOTHER | 1 | Sep 22, 2026 | clinicaltrials |
Data updated 6 days agoSource updated unknownsource: clinicaltrials